2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Monday, November 14, 2016

9:00AM-11:00AM: Abstract Number: 1171

Obesity and the Risk of Systemic Lupus Erythematosus in the Nurses’ Health Studies

Epidemiology and Public Health - Poster II

9:00AM-11:00AM: Abstract Number: 1294

Oblique Views Radiographs Have Advantages over Antero-Posterior View Radiographs in Assessing Sacroiliitis in Patients with Early Axial Spondyloarthritis

Imaging of Rheumatic Diseases - Poster II: XR/CT/PET/MRI

9:00AM-11:00AM: Abstract Number: 1947

Ocular Manifestations of ANCA-Associated Vasculitis

Vasculitis - Poster II: ANCA-Associated Vasculitis

9:00AM-11:00AM: Abstract Number: 1887

Olfactory Impairment Is Associate with Cognitive Dysfunction and Regional Brain Atrophy in Systemic Sclerosis

Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's – Clinical Aspects and Therapeutics - Poster II

9:00AM-11:00AM: Abstract Number: 1598

Olokizumab Treatment of Both Western and Asian Patients with Rheumatoid Arthritis Who Have Failed Anti-TNF Treatment Results in Sustained Improvements in Patient-Reported Outcomes

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster II

9:00AM-11:00AM: Abstract Number: 1506

One Third of Patients with Established Rheumatoid Arthritis (RA) Are Correctly Vaccinated Against Influenza and Pneumococcus and This Is Increasing: 3 Year Longitudinal Assessment of 776 Patients

Rheumatoid Arthritis – Clinical Aspects - Poster II: Co-morbidities and Complications

9:00AM-11:00AM: Abstract Number: 1182

Opiod Use and Death in Chronic Pain Patients with Systemic Lupus Erythematosis

Epidemiology and Public Health - Poster II

9:00AM-11:00AM: Abstract Number: 1850

Optimization of a Murine Model to Recapitulate Dermal and Pulmonary Features of SSc

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Pathogenesis, Animal Models and Genetics - Poster II

9:00AM-11:00AM: Abstract Number: 1239

Optimizing Screening for Psoriatic Arthritis through a Shortened Psoriatic Arthritis Screening and Evaluation-2 (PASE-2) Tool

Health Services Research - Poster II

9:00AM-11:00AM: Abstract Number: 1796

Osteoporosis and Vertebral Fractures in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis

Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster II: Damage Accrual and Quality of Life

9:00AM-11:00AM: Abstract Number: 1507

Our Strategy of Preventing Tuberculosis (TB) in Patients with Rheumatic Diseases Under the Treatment with Biologic Dmards

Rheumatoid Arthritis – Clinical Aspects - Poster II: Co-morbidities and Complications

9:00AM-11:00AM: Abstract Number: 1386

Outcome of 847 Childhood-Onset Systemic LUPUS Erythematousus Patients in Three Age Groups

Pediatric Rheumatology – Clinical and Therapeutic Aspects - Poster II: Myositis, Systemic Lupus Erythematosus, Sjögren's Syndrome

9:00AM-11:00AM: Abstract Number: 1525

Pain, Physical Function, and Worry (But Not Depression and Poor Sleep) Lead to Greater Fatigue in RA

Rheumatoid Arthritis – Clinical Aspects - Poster II: Co-morbidities and Complications

9:00AM-11:00AM: Abstract Number: 1915

Partial Elimination of Intestinal Microbiota Dampens T Helper 17 Cell Differentiation and Established Collagen-Induced Arthritis in Mice

T Cell Biology and Targets in Autoimmune Disease - Poster Session I

9:00AM-11:00AM: Abstract Number: 1428

Patient Attitudes Towards Being Prescribed Biosimilars in Inflammatory Autoimmune Diseases in Germany

Quality Measures and Quality of Care - Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].